不同剂量恩度胸腔灌注治疗肺癌恶性胸腔积液的效果及安全性观察

目的：本研究旨在观察不同剂量重组人血管内皮抑制素（恩度）胸腔灌注治疗非小细胞肺癌恶性胸腔积液的疗效及安全性。方法：将2017年1月至2020年6月在邢台市第一医院胸外科住院的病例中选取的92例恶性胸腔积液患者分为A、B、C3组，均留置中心静脉导管，均在充分穿刺抽液或引流后给药。胸腔灌注不同剂量的恩度，并进行总有效率及安全性的比较。结果：A、B、C3组胸腔分别注入恩度30 mg、60 mg、90 mg；总有效率分别为65.5%、75.0%、83.9%，但差异无统计学意义。恩度治疗恶性胸腔积液总体疗效较好。研究结果还显示，不良反应并不随剂量的增加而增加。结论：肺癌恶性胸腔积液患者胸腔灌注不同浓度的恩度整体疗效较好。不同剂量恩度胸腔灌注的疗效差异无统计学意义，且不良反应的发生率并不随剂量的增加而增加。

Clinical Efficacy and Safety of Different Dosages of Recombinant Human Endostatin for Intrapleural Perfusion in Non-small Cell Lung Cancer Patients with Malignant Pleural Effusion

Objective: To investigate the clinical efficacy and safety of different dosages of recombinant human endostatin (Rh-endostatin) in treatment of non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) by intrapleural injection. Methods: Ninety-two cases of NSCLC patients with MPE admitted in the Department of Thoracic Surgery, the First Hospital of Xingtai from January 2017 to June 2020 were divided into 3 groups in this study. All the patients underwent thoracic close drainage via central venous catheters, different dosages of Rh-endostatin were administrated through the catheters, and clinical efficacy and safety were compared. Results: Total clinical efficacy rates for 30 mg, 60 mg and 90 mg Rh-endostatin were 65.5%, 75.0% and 83.9%, respectively, without statistical significance. Rh-endostatin had a good overall effect in the treatment of MPE of NSCLC. The results also revealed that the incidences of adverse events (AEs) were not increased with the increase of the dosage. Conclusions: Therapeutic effects of different dosages of Rh-endostatin in the treatment of MPE of NSCLC are not statistically different, and the increase of dosage does not raise the incidence of AEs.